Postmenopausal women with hormone receptor-positive ( HR ( + ) ) breast cancer in whom disease progresses or there is recurrence while taking a nonsteroidal aromatase inhibitor ( NSAI ) are usually treated with exemestane ( EXE ) , but no single standard of care exists in this setting .